Tazverik

Overview

tazemetostat

methyltransferase inhibitor

• CYP3A4 substrate
• CYP2C8 inhibitor, weak
• CYP3A4 inducer, weak
• myelosuppressive oncologic agent
• prolongs QT interval (conditional)

• Withdrawn from US Market

Contraindicated

• pimozide
Tazverik (tazemetostat)

+

pimozide

1 interaction

Contraindicated

tazemetostat + pimozide

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ranolazine
Tazverik (tazemetostat)

+

ranolazine

1 interaction

Contraindicated

tazemetostat + ranolazine

contraindicated: combo may decr. ranolazine levels, efficacy (hepatic metabolism induced)

• thioridazine
Tazverik (tazemetostat)

+

thioridazine

1 interaction

Contraindicated

tazemetostat + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Avoid/Use Alternative

• adagrasib
Tazverik (tazemetostat)

+

adagrasib

1 interaction

Avoid/Use Alternative

tazemetostat + adagrasib

use alternative or monitor ECG, electrolytes, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• apalutamide
Tazverik (tazemetostat)

+

apalutamide

1 interaction

Avoid/Use Alternative

tazemetostat + apalutamide

avoid combo: combo may decr. tazemetostat levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• aprepitant
Tazverik (tazemetostat)

+

aprepitant

1 interaction

Avoid/Use Alternative

tazemetostat + aprepitant

if aprepitant 3-day regimen, use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid; aprepitant single dose-regimen OK: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. aprepitant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• arsenic trioxide
Tazverik (tazemetostat)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

tazemetostat + arsenic trioxide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• atazanavir
Tazverik (tazemetostat)

+

atazanavir

1 interaction

Avoid/Use Alternative

tazemetostat + atazanavir

avoid combo: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. atazanavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• avacopan
Tazverik (tazemetostat)

+

avacopan

1 interaction

Avoid/Use Alternative

tazemetostat + avacopan

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• bedaquiline
Tazverik (tazemetostat)

+

bedaquiline

1 interaction

Avoid/Use Alternative

tazemetostat + bedaquiline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• berotralstat
Tazverik (tazemetostat)

+

berotralstat

1 interaction

Avoid/Use Alternative

tazemetostat + berotralstat

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• bosentan
Tazverik (tazemetostat)

+

bosentan

1 interaction

Avoid/Use Alternative

tazemetostat + bosentan

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• butalbital
Tazverik (tazemetostat)

+

butalbital

1 interaction

Avoid/Use Alternative

tazemetostat + butalbital

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• carbamazepine
Tazverik (tazemetostat)

+

carbamazepine

1 interaction

Avoid/Use Alternative

tazemetostat + carbamazepine

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• cenobamate
Tazverik (tazemetostat)

+

cenobamate

1 interaction

Avoid/Use Alternative

tazemetostat + cenobamate

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• ceritinib
Tazverik (tazemetostat)

+

ceritinib

1 interaction

Avoid/Use Alternative

tazemetostat + ceritinib

use alternative or monitor ECG, electrolytes, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• chloramphenicol
Tazverik (tazemetostat)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

tazemetostat + chloramphenicol

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• ciprofloxacin
Tazverik (tazemetostat)

+

ciprofloxacin

1 interaction

Avoid/Use Alternative

tazemetostat + ciprofloxacin

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• cladribine oral
Tazverik (tazemetostat)

+

cladribine oral

1 interaction

Avoid/Use Alternative

tazemetostat + cladribine oral

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• clarithromycin
Tazverik (tazemetostat)

+

clarithromycin

1 interaction

Avoid/Use Alternative

tazemetostat + clarithromycin

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. clarithromycin levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• clofazimine
Tazverik (tazemetostat)

+

clofazimine

1 interaction

Avoid/Use Alternative

tazemetostat + clofazimine

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• cobicistat
Tazverik (tazemetostat)

+

cobicistat

1 interaction

Avoid/Use Alternative

tazemetostat + cobicistat

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. cobicistat levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• codeine
Tazverik (tazemetostat)

+

codeine

1 interaction

Avoid/Use Alternative

tazemetostat + codeine

use alternative or monitor withdrawal sx: combo may decr. codeine and active metabolite morphine levels, efficacy (hepatic metabolism induced, may decr. production of morphine)

• conivaptan
Tazverik (tazemetostat)

+

conivaptan

1 interaction

Avoid/Use Alternative

tazemetostat + conivaptan

during and x7 days after conivaptan tx, use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• crizotinib
Tazverik (tazemetostat)

+

crizotinib

1 interaction

Avoid/Use Alternative

tazemetostat + crizotinib

use alternative or monitor ECG, electrolytes, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. crizotinib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• cyclosporine
Tazverik (tazemetostat)

+

cyclosporine

1 interaction

Avoid/Use Alternative

tazemetostat + cyclosporine

use alternative or monitor ECG, CBC, cyclosporine levels; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. cyclosporine levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• dabrafenib
Tazverik (tazemetostat)

+

dabrafenib

1 interaction

Avoid/Use Alternative

tazemetostat + dabrafenib

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• danazol
Tazverik (tazemetostat)

+

danazol

1 interaction

Avoid/Use Alternative

tazemetostat + danazol

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• darunavir
Tazverik (tazemetostat)

+

darunavir

1 interaction

Avoid/Use Alternative

tazemetostat + darunavir

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. darunavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• deferiprone
Tazverik (tazemetostat)

+

deferiprone

1 interaction

Avoid/Use Alternative

tazemetostat + deferiprone

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• desogestrel (contraceptive)
Tazverik (tazemetostat)

+

desogestrel (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + desogestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. desogestrel levels, contraceptive efficacy (hepatic metabolism induced)

• dexrazoxane
Tazverik (tazemetostat)

+

dexrazoxane

1 interaction

Avoid/Use Alternative

tazemetostat + dexrazoxane

monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use, otherwise avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemo (additive effects; mechanism unknown)

• dienogest (contraceptive)
Tazverik (tazemetostat)

+

dienogest (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + dienogest (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. dienogest levels, contraceptive efficacy (hepatic metabolism induced)

• diltiazem
Tazverik (tazemetostat)

+

diltiazem

1 interaction

Avoid/Use Alternative

tazemetostat + diltiazem

use alternative or monitor ECG, CBC, BP, HR; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. diltiazem levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• dolutegravir
Tazverik (tazemetostat)

+

dolutegravir

1 interaction

Avoid/Use Alternative

tazemetostat + dolutegravir

avoid combo: combo may decr. dolutegravir levels, efficacy (hepatic metabolism induced)

• domperidone
Tazverik (tazemetostat)

+

domperidone

1 interaction

Avoid/Use Alternative

tazemetostat + domperidone

use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dronedarone
Tazverik (tazemetostat)

+

dronedarone

1 interaction

Avoid/Use Alternative

tazemetostat + dronedarone

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• drospirenone (contraceptive)
Tazverik (tazemetostat)

+

drospirenone (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + drospirenone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. drospirenone levels, contraceptive efficacy (hepatic metabolism induced)

• duvelisib
Tazverik (tazemetostat)

+

duvelisib

1 interaction

Avoid/Use Alternative

tazemetostat + duvelisib

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• efavirenz
Tazverik (tazemetostat)

+

efavirenz

1 interaction

Avoid/Use Alternative

tazemetostat + efavirenz

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• elagolix
Tazverik (tazemetostat)

+

elagolix

1 interaction

Avoid/Use Alternative

tazemetostat + elagolix

avoid combo if elagolix 300 mg bid regimen; otherwise, caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• encorafenib
Tazverik (tazemetostat)

+

encorafenib

1 interaction

Avoid/Use Alternative

tazemetostat + encorafenib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. tazemetostat levels, efficacy (additive effects; hepatic metabolism induced)

• enzalutamide
Tazverik (tazemetostat)

+

enzalutamide

1 interaction

Avoid/Use Alternative

tazemetostat + enzalutamide

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• ephedra
Tazverik (tazemetostat)

+

ephedra

1 interaction

Avoid/Use Alternative

tazemetostat + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Tazverik (tazemetostat)

+

erythromycin

1 interaction

Avoid/Use Alternative

tazemetostat + erythromycin

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• estradiol (contraceptive)
Tazverik (tazemetostat)

+

estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. estradiol levels, contraceptive efficacy (hepatic metabolism induced)

• ethinyl estradiol (contraceptive)
Tazverik (tazemetostat)

+

ethinyl estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + ethinyl estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced)

• ethynodiol (contraceptive)
Tazverik (tazemetostat)

+

ethynodiol (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + ethynodiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. ethynodiol and active metabolite levels, contraceptive efficacy (hepatic metabolism induced)

• etonogestrel (contraceptive)
Tazverik (tazemetostat)

+

etonogestrel (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + etonogestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. etonogestrel levels, contraceptive efficacy (hepatic metabolism induced)

• etravirine
Tazverik (tazemetostat)

+

etravirine

1 interaction

Avoid/Use Alternative

tazemetostat + etravirine

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• fedratinib
Tazverik (tazemetostat)

+

fedratinib

1 interaction

Avoid/Use Alternative

tazemetostat + fedratinib

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. fedratinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• fentanyl
Tazverik (tazemetostat)

+

fentanyl

1 interaction

Avoid/Use Alternative

tazemetostat + fentanyl

use alternative or monitor withdrawal sx: combo may decr. fentanyl levels, efficacy (hepatic metabolism induced)

• fexinidazole
Tazverik (tazemetostat)

+

fexinidazole

1 interaction

Avoid/Use Alternative

tazemetostat + fexinidazole

avoid combo during and x7 days after fexinidazole tx; if possible, do not initiate fexinidazole until 5 half-lives after tazemetostat D/C: combo may decr. tazemetostat levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (hepatic metabolism induced; additive effects)

• fluconazole
Tazverik (tazemetostat)

+

fluconazole

1 interaction

Avoid/Use Alternative

tazemetostat + fluconazole

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• fosamprenavir
Tazverik (tazemetostat)

+

fosamprenavir

1 interaction

Avoid/Use Alternative

tazemetostat + fosamprenavir

avoid combo: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. amprenavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• fosfomycin injection
Tazverik (tazemetostat)

+

fosfomycin injection

1 interaction

Avoid/Use Alternative

tazemetostat + fosfomycin injection

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• fosphenytoin
Tazverik (tazemetostat)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

tazemetostat + fosphenytoin

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• ganciclovir
Tazverik (tazemetostat)

+

ganciclovir

1 interaction

Avoid/Use Alternative

tazemetostat + ganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• grapefruit
Tazverik (tazemetostat)

+

grapefruit

1 interaction

Avoid/Use Alternative

tazemetostat + grapefruit

avoid combo: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (GI metabolism inhibited)

• hydroxychloroquine
Tazverik (tazemetostat)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

tazemetostat + hydroxychloroquine

use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• idelalisib
Tazverik (tazemetostat)

+

idelalisib

1 interaction

Avoid/Use Alternative

tazemetostat + idelalisib

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• imatinib
Tazverik (tazemetostat)

+

imatinib

1 interaction

Avoid/Use Alternative

tazemetostat + imatinib

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• isavuconazonium
Tazverik (tazemetostat)

+

isavuconazonium

1 interaction

Avoid/Use Alternative

tazemetostat + isavuconazonium

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. isavuconazole levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• itraconazole
Tazverik (tazemetostat)

+

itraconazole

1 interaction

Avoid/Use Alternative

tazemetostat + itraconazole

during and x2wk after itraconazole tx, use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. itraconazole levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• ivosidenib
Tazverik (tazemetostat)

+

ivosidenib

1 interaction

Avoid/Use Alternative

tazemetostat + ivosidenib

avoid combo: combo may decr. tazemetostat levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• ketoconazole
Tazverik (tazemetostat)

+

ketoconazole

1 interaction

Avoid/Use Alternative

tazemetostat + ketoconazole

during and up to 1wk after ketoconazole tx, use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. ketoconazole levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• lefamulin
Tazverik (tazemetostat)

+

lefamulin

1 interaction

Avoid/Use Alternative

tazemetostat + lefamulin

ORAL LEFAMULIN: use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid; IV lefamulin use OK: combo with oral lefamulin may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. lefamulin levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• lenacapavir
Tazverik (tazemetostat)

+

lenacapavir

1 interaction

Avoid/Use Alternative

tazemetostat + lenacapavir

during and x9mo after lenacapavir tx, use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. lenacapavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• letermovir
Tazverik (tazemetostat)

+

letermovir

1 interaction

Avoid/Use Alternative

tazemetostat + letermovir

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. letermovir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• levoketoconazole
Tazverik (tazemetostat)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

tazemetostat + levoketoconazole

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. levoketoconazole levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• levonorgestrel (contraceptive)
Tazverik (tazemetostat)

+

levonorgestrel (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + levonorgestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. levonorgestrel levels, contraceptive efficacy (hepatic metabolism induced)

• levonorgestrel (post-coital contraceptive)
Tazverik (tazemetostat)

+

levonorgestrel (post-coital contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + levonorgestrel (post-coital contraceptive)

consider alternative: combo may decr. levonorgestrel levels, post-coital contraceptive efficacy (hepatic metabolism induced)

• lonafarnib
Tazverik (tazemetostat)

+

lonafarnib

1 interaction

Avoid/Use Alternative

tazemetostat + lonafarnib

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. lonafarnib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• lopinavir/ritonavir
Tazverik (tazemetostat)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

tazemetostat + lopinavir/ ritonavir

avoid combo: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. levels of both drugs, efficacy (hepatic metabolism altered)

• lorlatinib
Tazverik (tazemetostat)

+

lorlatinib

1 interaction

Avoid/Use Alternative

tazemetostat + lorlatinib

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• lumacaftor/ivacaftor
Tazverik (tazemetostat)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

tazemetostat + lumacaftor/ ivacaftor

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• lumateperone
Tazverik (tazemetostat)

+

lumateperone

1 interaction

Avoid/Use Alternative

tazemetostat + lumateperone

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• mavacamten
Tazverik (tazemetostat)

+

mavacamten

1 interaction

Avoid/Use Alternative

tazemetostat + mavacamten

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• medroxyprogesterone (contraceptive)
Tazverik (tazemetostat)

+

medroxyprogesterone (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + medroxyprogesterone (contraceptive)

use additional non-hormonal or alternative contraception: combo may decr. medroxyprogesterone levels, contraceptive efficacy (hepatic metabolism induced)

• meperidine
Tazverik (tazemetostat)

+

meperidine

1 interaction

Avoid/Use Alternative

tazemetostat + meperidine

use alternative or monitor for withdrawal sx: combo may decr. meperidine levels, efficacy; may incr. normeperidine levels, risk of neurotoxicity (hepatic metabolism induced, incr. toxic metabolite formation)

• mifepristone
Tazverik (tazemetostat)

+

mifepristone

1 interaction

Avoid/Use Alternative

tazemetostat + mifepristone

during and x14 days after daily mifepristone use, use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• mitapivat
Tazverik (tazemetostat)

+

mitapivat

1 interaction

Avoid/Use Alternative

tazemetostat + mitapivat

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• mitotane
Tazverik (tazemetostat)

+

mitotane

1 interaction

Avoid/Use Alternative

tazemetostat + mitotane

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• mobocertinib
Tazverik (tazemetostat)

+

mobocertinib

1 interaction

Avoid/Use Alternative

tazemetostat + mobocertinib

use alternative or monitor ECG, electrolytes: combo may decr. levels of both drugs, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• modafinil
Tazverik (tazemetostat)

+

modafinil

1 interaction

Avoid/Use Alternative

tazemetostat + modafinil

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• nafcillin
Tazverik (tazemetostat)

+

nafcillin

1 interaction

Avoid/Use Alternative

tazemetostat + nafcillin

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• nefazodone
Tazverik (tazemetostat)

+

nefazodone

1 interaction

Avoid/Use Alternative

tazemetostat + nefazodone

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. nefazodone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• nelfinavir
Tazverik (tazemetostat)

+

nelfinavir

1 interaction

Avoid/Use Alternative

tazemetostat + nelfinavir

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. nelfinavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• netupitant
Tazverik (tazemetostat)

+

netupitant

1 interaction

Avoid/Use Alternative

tazemetostat + netupitant

during and x1wk after (fos)netupitant tx, use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. netupitant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• nilotinib
Tazverik (tazemetostat)

+

nilotinib

1 interaction

Avoid/Use Alternative

tazemetostat + nilotinib

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• nirogacestat
Tazverik (tazemetostat)

+

nirogacestat

1 interaction

Avoid/Use Alternative

tazemetostat + nirogacestat

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. nirogacestat levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• norelgestromin (contraceptive)
Tazverik (tazemetostat)

+

norelgestromin (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + norelgestromin (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. norelgestromin levels, contraceptive efficacy (hepatic metabolism induced)

• norethindrone (contraceptive)
Tazverik (tazemetostat)

+

norethindrone (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + norethindrone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. norethindrone levels, contraceptive efficacy (hepatic metabolism induced)

• norgestimate (contraceptive)
Tazverik (tazemetostat)

+

norgestimate (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + norgestimate (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. norgestimate and active metabolites levels, contraceptive efficacy (hepatic metabolism induced)

• norgestrel (contraceptive)
Tazverik (tazemetostat)

+

norgestrel (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + norgestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

• oliceridine
Tazverik (tazemetostat)

+

oliceridine

1 interaction

Avoid/Use Alternative

tazemetostat + oliceridine

use alternative or monitor withdrawal sx; consider oliceridine dose adjustment: combo may decr. oliceridine levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• oxycodone
Tazverik (tazemetostat)

+

oxycodone

1 interaction

Avoid/Use Alternative

tazemetostat + oxycodone

use alternative or monitor withdrawal sx: combo may decr. oxycodone levels, efficacy (hepatic metabolism induced)

• pacritinib
Tazverik (tazemetostat)

+

pacritinib

1 interaction

Avoid/Use Alternative

tazemetostat + pacritinib

avoid combo: combo may decr. tazemetostat levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• palifermin
Tazverik (tazemetostat)

+

palifermin

1 interaction

Avoid/Use Alternative

tazemetostat + palifermin

avoid palifermin admin. w/in 24h before, during tx, or w/in 24h after myelotoxic chemo; otherwise, caution advised: combo may incr. severity and duration of oral mucositis (antagonistic effects)

• penicillamine
Tazverik (tazemetostat)

+

penicillamine

1 interaction

Avoid/Use Alternative

tazemetostat + penicillamine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pentamidine
Tazverik (tazemetostat)

+

pentamidine

1 interaction

Avoid/Use Alternative

tazemetostat + pentamidine

use alternative or monitor ECG, CBC; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• pentobarbital
Tazverik (tazemetostat)

+

pentobarbital

1 interaction

Avoid/Use Alternative

tazemetostat + pentobarbital

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• pexidartinib
Tazverik (tazemetostat)

+

pexidartinib

1 interaction

Avoid/Use Alternative

tazemetostat + pexidartinib

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• phenobarbital
Tazverik (tazemetostat)

+

phenobarbital

1 interaction

Avoid/Use Alternative

tazemetostat + phenobarbital

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• phenytoin
Tazverik (tazemetostat)

+

phenytoin

1 interaction

Avoid/Use Alternative

tazemetostat + phenytoin

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• posaconazole
Tazverik (tazemetostat)

+

posaconazole

1 interaction

Avoid/Use Alternative

tazemetostat + posaconazole

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• primaquine
Tazverik (tazemetostat)

+

primaquine

1 interaction

Avoid/Use Alternative

tazemetostat + primaquine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• primidone
Tazverik (tazemetostat)

+

primidone

1 interaction

Avoid/Use Alternative

tazemetostat + primidone

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• quizartinib
Tazverik (tazemetostat)

+

quizartinib

1 interaction

Avoid/Use Alternative

tazemetostat + quizartinib

use alternative or monitor ECG, electrolytes: combo may decr. quizartinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• radium Ra 223 dichloride
Tazverik (tazemetostat)

+

radium Ra 223 dichloride

1 interaction

Avoid/Use Alternative

tazemetostat + radium Ra 223 dichloride

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• relacorilant
Tazverik (tazemetostat)

+

relacorilant

1 interaction

Avoid/Use Alternative

tazemetostat + relacorilant

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• repotrectinib
Tazverik (tazemetostat)

+

repotrectinib

1 interaction

Avoid/Use Alternative

tazemetostat + repotrectinib

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• ribociclib
Tazverik (tazemetostat)

+

ribociclib

1 interaction

Avoid/Use Alternative

tazemetostat + ribociclib

use alternative or monitor ECG, electrolytes, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. ribociclib levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• rifabutin
Tazverik (tazemetostat)

+

rifabutin

1 interaction

Avoid/Use Alternative

tazemetostat + rifabutin

avoid combo: combo may decr. tazemetostat levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism induced; additive effects)

• rifampin
Tazverik (tazemetostat)

+

rifampin

1 interaction

Avoid/Use Alternative

tazemetostat + rifampin

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• rifapentine
Tazverik (tazemetostat)

+

rifapentine

1 interaction

Avoid/Use Alternative

tazemetostat + rifapentine

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• rilzabrutinib
Tazverik (tazemetostat)

+

rilzabrutinib

1 interaction

Avoid/Use Alternative

tazemetostat + rilzabrutinib

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• ritonavir
Tazverik (tazemetostat)

+

ritonavir

1 interaction

Avoid/Use Alternative

tazemetostat + ritonavir

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. ritonavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• ropeginterferon alfa-2b
Tazverik (tazemetostat)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

tazemetostat + ropeginterferon alfa-2b

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• segesterone (contraceptive)
Tazverik (tazemetostat)

+

segesterone (contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + segesterone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after tazemetostat tx: combo may decr. segesterone levels, contraceptive efficacy (hepatic metabolism induced)

• sotalol
Tazverik (tazemetostat)

+

sotalol

1 interaction

Avoid/Use Alternative

tazemetostat + sotalol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotorasib
Tazverik (tazemetostat)

+

sotorasib

1 interaction

Avoid/Use Alternative

tazemetostat + sotorasib

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• St. John's wort
Tazverik (tazemetostat)

+

St. John's wort

1 interaction

Avoid/Use Alternative

tazemetostat + St. John's wort

avoid combo: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• tipranavir
Tazverik (tazemetostat)

+

tipranavir

1 interaction

Avoid/Use Alternative

tazemetostat + tipranavir

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. tipranavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• toremifene
Tazverik (tazemetostat)

+

toremifene

1 interaction

Avoid/Use Alternative

tazemetostat + toremifene

use alternative or monitor ECG: combo may decr. toremifene levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• tramadol
Tazverik (tazemetostat)

+

tramadol

1 interaction

Avoid/Use Alternative

tazemetostat + tramadol

use alternative or monitor withdrawal sx, ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. tramadol levels, efficacy (additive effects; hepatic metabolism induced)

• tucatinib
Tazverik (tazemetostat)

+

tucatinib

1 interaction

Avoid/Use Alternative

tazemetostat + tucatinib

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• ulipristal (post-coital contraceptive)
Tazverik (tazemetostat)

+

ulipristal (post-coital contraceptive)

1 interaction

Avoid/Use Alternative

tazemetostat + ulipristal (post-coital contraceptive)

avoid combo: combo may decr. ulipristal levels, post-coital contraceptive efficacy (hepatic metabolism induced)

• valganciclovir
Tazverik (tazemetostat)

+

valganciclovir

1 interaction

Avoid/Use Alternative

tazemetostat + valganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vandetanib
Tazverik (tazemetostat)

+

vandetanib

1 interaction

Avoid/Use Alternative

tazemetostat + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• verapamil
Tazverik (tazemetostat)

+

verapamil

1 interaction

Avoid/Use Alternative

tazemetostat + verapamil

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. verapamil levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• voriconazole
Tazverik (tazemetostat)

+

voriconazole

1 interaction

Avoid/Use Alternative

tazemetostat + voriconazole

use alternative or monitor ECG, CBC, breakthrough fungal infection; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. voriconazole levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• ziprasidone
Tazverik (tazemetostat)

+

ziprasidone

1 interaction

Avoid/Use Alternative

tazemetostat + ziprasidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• zuranolone
Tazverik (tazemetostat)

+

zuranolone

1 interaction

Avoid/Use Alternative

tazemetostat + zuranolone

avoid combo: combo may decr. zuranolone levels, efficacy (hepatic metabolism induced)

Monitor/Modify Tx

• aficamten
Tazverik (tazemetostat)

+

aficamten

1 interaction

Monitor/Modify Tx

tazemetostat + aficamten

monitor cardiac fxn, incl. LVEF: combo may decr. aficamten levels, efficacy (hepatic metabolism induced)

• albendazole
Tazverik (tazemetostat)

+

albendazole

1 interaction

Monitor/Modify Tx

tazemetostat + albendazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• alemtuzumab
Tazverik (tazemetostat)

+

alemtuzumab

1 interaction

Monitor/Modify Tx

tazemetostat + alemtuzumab

monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

• allopurinol
Tazverik (tazemetostat)

+

allopurinol

1 interaction

Monitor/Modify Tx

tazemetostat + allopurinol

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• amiodarone
Tazverik (tazemetostat)

+

amiodarone

1 interaction

Monitor/Modify Tx

tazemetostat + amiodarone

monitor ECG: combo may incr. or decr. amiodarone levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered, additive effects)

• amlodipine
Tazverik (tazemetostat)

+

amlodipine

1 interaction

Monitor/Modify Tx

tazemetostat + amlodipine

monitor BP: combo may decr. amlodipine levels, efficacy (hepatic metabolism induced)

• anagrelide
Tazverik (tazemetostat)

+

anagrelide

1 interaction

Monitor/Modify Tx

tazemetostat + anagrelide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• anti-thymocyte globulin
Tazverik (tazemetostat)

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

tazemetostat + anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• apomorphine
Tazverik (tazemetostat)

+

apomorphine

1 interaction

Monitor/Modify Tx

tazemetostat + apomorphine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Tazverik (tazemetostat)

+

artemether/ lumefantrine

1 interaction

Monitor/Modify Tx

tazemetostat + artemether/ lumefantrine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. levels of both drugs, efficacy (additive effects; hepatic metabolism induced)

• asenapine
Tazverik (tazemetostat)

+

asenapine

1 interaction

Monitor/Modify Tx

tazemetostat + asenapine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• atidarsagene autotemcel
Tazverik (tazemetostat)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

tazemetostat + atidarsagene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• atogepant
Tazverik (tazemetostat)

+

atogepant

1 interaction

Monitor/Modify Tx

tazemetostat + atogepant

CHRONIC MIGRAINE: incr. atogepant dose to 60 mg/day; EPISODIC MIGRAINE: incr. atogepant dose to 30 or 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

• auranofin
Tazverik (tazemetostat)

+

auranofin

1 interaction

Monitor/Modify Tx

tazemetostat + auranofin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• azathioprine
Tazverik (tazemetostat)

+

azathioprine

1 interaction

Monitor/Modify Tx

tazemetostat + azathioprine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• azithromycin
Tazverik (tazemetostat)

+

azithromycin

1 interaction

Monitor/Modify Tx

tazemetostat + azithromycin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• balsalazide
Tazverik (tazemetostat)

+

balsalazide

1 interaction

Monitor/Modify Tx

tazemetostat + balsalazide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• baricitinib
Tazverik (tazemetostat)

+

baricitinib

1 interaction

Monitor/Modify Tx

tazemetostat + baricitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• benznidazole
Tazverik (tazemetostat)

+

benznidazole

1 interaction

Monitor/Modify Tx

tazemetostat + benznidazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• betibeglogene autotemcel
Tazverik (tazemetostat)

+

betibeglogene autotemcel

1 interaction

Monitor/Modify Tx

tazemetostat + betibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• buprenorphine
Tazverik (tazemetostat)

+

buprenorphine

1 interaction

Monitor/Modify Tx

tazemetostat + buprenorphine

monitor withdrawal sx: combo may decr. buprenorphine levels, efficacy (hepatic metabolism induced)

• cabozantinib
Tazverik (tazemetostat)

+

cabozantinib

1 interaction

Monitor/Modify Tx

tazemetostat + cabozantinib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. cabozantinib levels, efficacy (additive effects; hepatic metabolism induced)

• chloroquine
Tazverik (tazemetostat)

+

chloroquine

1 interaction

Monitor/Modify Tx

tazemetostat + chloroquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cidofovir
Tazverik (tazemetostat)

+

cidofovir

1 interaction

Monitor/Modify Tx

tazemetostat + cidofovir

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• citalopram
Tazverik (tazemetostat)

+

citalopram

1 interaction

Monitor/Modify Tx

tazemetostat + citalopram

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clozapine
Tazverik (tazemetostat)

+

clozapine

1 interaction

Monitor/Modify Tx

tazemetostat + clozapine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• colchicine
Tazverik (tazemetostat)

+

colchicine

1 interaction

Monitor/Modify Tx

tazemetostat + colchicine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• copper histidinate
Tazverik (tazemetostat)

+

copper histidinate

1 interaction

Monitor/Modify Tx

tazemetostat + copper histidinate

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cyclophosphamide
Tazverik (tazemetostat)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

tazemetostat + cyclophosphamide

monitor CBC, renal, cardiac fxn: combo may incr. cyclophosphamide active metabolite levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (hepatic metabolism possibly induced, incr. active metabolite formation; additive effects)

• dapsone
Tazverik (tazemetostat)

+

dapsone

1 interaction

Monitor/Modify Tx

tazemetostat + dapsone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• deferasirox
Tazverik (tazemetostat)

+

deferasirox

1 interaction

Monitor/Modify Tx

tazemetostat + deferasirox

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• degarelix
Tazverik (tazemetostat)

+

degarelix

1 interaction

Monitor/Modify Tx

tazemetostat + degarelix

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Tazverik (tazemetostat)

+

desflurane

1 interaction

Monitor/Modify Tx

tazemetostat + desflurane

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Tazverik (tazemetostat)

+

desipramine

1 interaction

Monitor/Modify Tx

tazemetostat + desipramine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• deuruxolitinib
Tazverik (tazemetostat)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

tazemetostat + deuruxolitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• dexmedetomidine
Tazverik (tazemetostat)

+

dexmedetomidine

1 interaction

Monitor/Modify Tx

tazemetostat + dexmedetomidine

monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Tazverik (tazemetostat)

+

dexmedetomidine injection

1 interaction

Monitor/Modify Tx

tazemetostat + dexmedetomidine injection

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• disopyramide
Tazverik (tazemetostat)

+

disopyramide

1 interaction

Monitor/Modify Tx

tazemetostat + disopyramide

monitor disopyramide levels, ECG: combo may decr. disopyramide levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• dofetilide
Tazverik (tazemetostat)

+

dofetilide

1 interaction

Monitor/Modify Tx

tazemetostat + dofetilide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• donepezil
Tazverik (tazemetostat)

+

donepezil

1 interaction

Monitor/Modify Tx

tazemetostat + donepezil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dordaviprone
Tazverik (tazemetostat)

+

dordaviprone

1 interaction

Monitor/Modify Tx

tazemetostat + dordaviprone

monitor ECG, electrolytes: combo may decr. dordaviprone levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• droperidol
Tazverik (tazemetostat)

+

droperidol

1 interaction

Monitor/Modify Tx

tazemetostat + droperidol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• efbemalenograstim alfa
Tazverik (tazemetostat)

+

efbemalenograstim alfa

1 interaction

Monitor/Modify Tx

tazemetostat + efbemalenograstim alfa

admin. efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

• eflapegrastim (G-CSF)
Tazverik (tazemetostat)

+

eflapegrastim (G-CSF)

1 interaction

Monitor/Modify Tx

tazemetostat + eflapegrastim (G-CSF)

admin. eflapegrastim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

• elivaldogene autotemcel
Tazverik (tazemetostat)

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

tazemetostat + elivaldogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• epirubicin
Tazverik (tazemetostat)

+

epirubicin

1 interaction

Monitor/Modify Tx

tazemetostat + epirubicin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eribulin
Tazverik (tazemetostat)

+

eribulin

1 interaction

Monitor/Modify Tx

tazemetostat + eribulin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• etuvetidigene autotemcel
Tazverik (tazemetostat)

+

etuvetidigene autotemcel

1 interaction

Monitor/Modify Tx

tazemetostat + etuvetidigene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• everolimus
Tazverik (tazemetostat)

+

everolimus

1 interaction

Monitor/Modify Tx

tazemetostat + everolimus

monitor CBC; BREAST CA, PNET, RENAL CELL CA, RENAL ANGIOMYOLIPOMA W/ TSC: caution advised; TSC-ASSOC. SEGA or TSC-ASSOC. PARTIAL-ONSET SEIZURES, TRANSPLANT: monitor everolimus levels: combo may incr. risk of myelosuppression; may decr. everolimus levels, efficacy (additive effects; hepatic metabolism induced)

• exagamglogene autotemcel
Tazverik (tazemetostat)

+

exagamglogene autotemcel

1 interaction

Monitor/Modify Tx

tazemetostat + exagamglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• filgrastim (G-CSF)
Tazverik (tazemetostat)

+

filgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

tazemetostat + filgrastim (G-CSF)

admin. filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

• flecainide
Tazverik (tazemetostat)

+

flecainide

1 interaction

Monitor/Modify Tx

tazemetostat + flecainide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flucytosine
Tazverik (tazemetostat)

+

flucytosine

1 interaction

Monitor/Modify Tx

tazemetostat + flucytosine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fluorouracil
Tazverik (tazemetostat)

+

fluorouracil

1 interaction

Monitor/Modify Tx

tazemetostat + fluorouracil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluphenazine
Tazverik (tazemetostat)

+

fluphenazine

1 interaction

Monitor/Modify Tx

tazemetostat + fluphenazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• foscarnet
Tazverik (tazemetostat)

+

foscarnet

1 interaction

Monitor/Modify Tx

tazemetostat + foscarnet

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fostamatinib
Tazverik (tazemetostat)

+

fostamatinib

1 interaction

Monitor/Modify Tx

tazemetostat + fostamatinib

monitor CBC: combo may incr. risk of myelosuppression; may decr. fostamatinib active metabolite levels, efficacy (additive effects; hepatic metabolism induced)

• gilteritinib
Tazverik (tazemetostat)

+

gilteritinib

1 interaction

Monitor/Modify Tx

tazemetostat + gilteritinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. gilteritinib levels, efficacy (additive effects; hepatic metabolism induced)

• givinostat
Tazverik (tazemetostat)

+

givinostat

1 interaction

Monitor/Modify Tx

tazemetostat + givinostat

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• glasdegib
Tazverik (tazemetostat)

+

glasdegib

1 interaction

Monitor/Modify Tx

tazemetostat + glasdegib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. glasdegib levels, efficacy (additive effects; hepatic metabolism induced)

• goserelin
Tazverik (tazemetostat)

+

goserelin

1 interaction

Monitor/Modify Tx

tazemetostat + goserelin

PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• haloperidol
Tazverik (tazemetostat)

+

haloperidol

1 interaction

Monitor/Modify Tx

tazemetostat + haloperidol

monitor ECG, electrolytes: combo may decr. haloperidol levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• histrelin
Tazverik (tazemetostat)

+

histrelin

1 interaction

Monitor/Modify Tx

tazemetostat + histrelin

consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hydroxyurea
Tazverik (tazemetostat)

+

hydroxyurea

1 interaction

Monitor/Modify Tx

tazemetostat + hydroxyurea

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• hydroxyzine
Tazverik (tazemetostat)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

tazemetostat + hydroxyzine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibutilide
Tazverik (tazemetostat)

+

ibutilide

1 interaction

Monitor/Modify Tx

tazemetostat + ibutilide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ifosfamide
Tazverik (tazemetostat)

+

ifosfamide

1 interaction

Monitor/Modify Tx

tazemetostat + ifosfamide

monitor CBC, renal, cardiac fxn; consider ifosfamide dose adjustment: combo may incr. ifosfamide active and toxic metabolite levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects (hepatic metabolism induced, incr. metabolite formation)

• inotuzumab ozogamicin
Tazverik (tazemetostat)

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

tazemetostat + inotuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• interferon beta 1a
Tazverik (tazemetostat)

+

interferon beta 1a

1 interaction

Monitor/Modify Tx

tazemetostat + interferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon beta 1b
Tazverik (tazemetostat)

+

interferon beta 1b

1 interaction

Monitor/Modify Tx

tazemetostat + interferon beta 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon gamma 1b
Tazverik (tazemetostat)

+

interferon gamma 1b

1 interaction

Monitor/Modify Tx

tazemetostat + interferon gamma 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• isoflurane
Tazverik (tazemetostat)

+

isoflurane

1 interaction

Monitor/Modify Tx

tazemetostat + isoflurane

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isradipine
Tazverik (tazemetostat)

+

isradipine

1 interaction

Monitor/Modify Tx

tazemetostat + isradipine

monitor BP: combo may decr. isradipine levels, efficacy (hepatic metabolism induced)

• leflunomide
Tazverik (tazemetostat)

+

leflunomide

1 interaction

Monitor/Modify Tx

tazemetostat + leflunomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• leuprolide
Tazverik (tazemetostat)

+

leuprolide

1 interaction

Monitor/Modify Tx

tazemetostat + leuprolide

PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Tazverik (tazemetostat)

+

levofloxacin

1 interaction

Monitor/Modify Tx

tazemetostat + levofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• linezolid
Tazverik (tazemetostat)

+

linezolid

1 interaction

Monitor/Modify Tx

tazemetostat + linezolid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lofexidine
Tazverik (tazemetostat)

+

lofexidine

1 interaction

Monitor/Modify Tx

tazemetostat + lofexidine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lovotibeglogene autotemcel
Tazverik (tazemetostat)

+

lovotibeglogene autotemcel

1 interaction

Monitor/Modify Tx

tazemetostat + lovotibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Tazverik (tazemetostat)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

tazemetostat + lymphocyte immune globulin, anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• macimorelin
Tazverik (tazemetostat)

+

macimorelin

1 interaction

Monitor/Modify Tx

tazemetostat + macimorelin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• marnetegragene autotemcel
Tazverik (tazemetostat)

+

marnetegragene autotemcel

1 interaction

Monitor/Modify Tx

tazemetostat + marnetegragene autotemcel

monitor CBC, bleeding signs/symptoms: combo may incr. risk of myelosuppression (additive effects)

• mercaptopurine
Tazverik (tazemetostat)

+

mercaptopurine

1 interaction

Monitor/Modify Tx

tazemetostat + mercaptopurine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine
Tazverik (tazemetostat)

+

mesalamine

1 interaction

Monitor/Modify Tx

tazemetostat + mesalamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine rectal
Tazverik (tazemetostat)

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

tazemetostat + mesalamine rectal

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• methadone
Tazverik (tazemetostat)

+

methadone

1 interaction

Monitor/Modify Tx

tazemetostat + methadone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. methadone levels, efficacy (additive effects; hepatic metabolism induced)

• methotrexate
Tazverik (tazemetostat)

+

methotrexate

1 interaction

Monitor/Modify Tx

tazemetostat + methotrexate

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• moxifloxacin
Tazverik (tazemetostat)

+

moxifloxacin

1 interaction

Monitor/Modify Tx

tazemetostat + moxifloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mycophenolate mofetil
Tazverik (tazemetostat)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

tazemetostat + mycophenolate mofetil

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mycophenolic acid
Tazverik (tazemetostat)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

tazemetostat + mycophenolic acid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• nicardipine
Tazverik (tazemetostat)

+

nicardipine

1 interaction

Monitor/Modify Tx

tazemetostat + nicardipine

monitor BP: combo may decr. nicardipine levels, efficacy (hepatic metabolism induced)

• nimodipine
Tazverik (tazemetostat)

+

nimodipine

1 interaction

Monitor/Modify Tx

tazemetostat + nimodipine

monitor BP: combo may decr. nimodipine levels, efficacy (hepatic metabolism induced)

• nisoldipine
Tazverik (tazemetostat)

+

nisoldipine

1 interaction

Monitor/Modify Tx

tazemetostat + nisoldipine

monitor BP: combo may decr. nisoldipine levels, efficacy (hepatic metabolism induced)

• olsalazine
Tazverik (tazemetostat)

+

olsalazine

1 interaction

Monitor/Modify Tx

tazemetostat + olsalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ondansetron
Tazverik (tazemetostat)

+

ondansetron

1 interaction

Monitor/Modify Tx

tazemetostat + ondansetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osimertinib
Tazverik (tazemetostat)

+

osimertinib

1 interaction

Monitor/Modify Tx

tazemetostat + osimertinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• paclitaxel
Tazverik (tazemetostat)

+

paclitaxel

1 interaction

Monitor/Modify Tx

tazemetostat + paclitaxel

monitor CBC: combo may incr. paclitaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• paliperidone
Tazverik (tazemetostat)

+

paliperidone

1 interaction

Monitor/Modify Tx

tazemetostat + paliperidone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palonosetron
Tazverik (tazemetostat)

+

palonosetron

1 interaction

Monitor/Modify Tx

tazemetostat + palonosetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pasireotide
Tazverik (tazemetostat)

+

pasireotide

1 interaction

Monitor/Modify Tx

tazemetostat + pasireotide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pegfilgrastim (G-CSF)
Tazverik (tazemetostat)

+

pegfilgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

tazemetostat + pegfilgrastim (G-CSF)

admin. pegfilgrastim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

• peginterferon alfa 2a
Tazverik (tazemetostat)

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

tazemetostat + peginterferon alfa 2a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• peginterferon beta 1a
Tazverik (tazemetostat)

+

peginterferon beta 1a

1 interaction

Monitor/Modify Tx

tazemetostat + peginterferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• procainamide
Tazverik (tazemetostat)

+

procainamide

1 interaction

Monitor/Modify Tx

tazemetostat + procainamide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• proguanil
Tazverik (tazemetostat)

+

proguanil

1 interaction

Monitor/Modify Tx

tazemetostat + proguanil

monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

• propafenone
Tazverik (tazemetostat)

+

propafenone

1 interaction

Monitor/Modify Tx

tazemetostat + propafenone

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pyrimethamine
Tazverik (tazemetostat)

+

pyrimethamine

1 interaction

Monitor/Modify Tx

tazemetostat + pyrimethamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• quinidine (antiarrhythmic)
Tazverik (tazemetostat)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

tazemetostat + quinidine (antiarrhythmic)

monitor quinidine levels, ECG: combo may decr. quinidine levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• quinidine (CYP2D6 inhibitor)
Tazverik (tazemetostat)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Monitor/Modify Tx

tazemetostat + quinidine (CYP2D6 inhibitor)

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinine
Tazverik (tazemetostat)

+

quinine

1 interaction

Monitor/Modify Tx

tazemetostat + quinine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. quinine levels, efficacy (additive effects; hepatic metabolism induced)

• repaglinide
Tazverik (tazemetostat)

+

repaglinide

1 interaction

Monitor/Modify Tx

tazemetostat + repaglinide

monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• revumenib
Tazverik (tazemetostat)

+

revumenib

1 interaction

Monitor/Modify Tx

tazemetostat + revumenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribavirin
Tazverik (tazemetostat)

+

ribavirin

1 interaction

Monitor/Modify Tx

tazemetostat + ribavirin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rituximab
Tazverik (tazemetostat)

+

rituximab

1 interaction

Monitor/Modify Tx

tazemetostat + rituximab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• romidepsin
Tazverik (tazemetostat)

+

romidepsin

1 interaction

Monitor/Modify Tx

tazemetostat + romidepsin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rucaparib
Tazverik (tazemetostat)

+

rucaparib

1 interaction

Monitor/Modify Tx

tazemetostat + rucaparib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ruxolitinib topical
Tazverik (tazemetostat)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

tazemetostat + ruxolitinib topical

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sargramostim (GM-CSF)
Tazverik (tazemetostat)

+

sargramostim (GM-CSF)

1 interaction

Monitor/Modify Tx

tazemetostat + sargramostim (GM-CSF)

admin. sargramostim at least 24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

• sarilumab
Tazverik (tazemetostat)

+

sarilumab

1 interaction

Monitor/Modify Tx

tazemetostat + sarilumab

monitor CBC: combo may decr. tazemetostat levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C; additive effects)

• satralizumab
Tazverik (tazemetostat)

+

satralizumab

1 interaction

Monitor/Modify Tx

tazemetostat + satralizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• selpercatinib
Tazverik (tazemetostat)

+

selpercatinib

1 interaction

Monitor/Modify Tx

tazemetostat + selpercatinib

monitor ECG, electrolytes: combo may decr. selpercatinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• sevoflurane
Tazverik (tazemetostat)

+

sevoflurane

1 interaction

Monitor/Modify Tx

tazemetostat + sevoflurane

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sirolimus
Tazverik (tazemetostat)

+

sirolimus

1 interaction

Monitor/Modify Tx

tazemetostat + sirolimus

monitor sirolimus levels, CBC: combo may decr. sirolimus levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism induced; additive effects)

• stiripentol
Tazverik (tazemetostat)

+

stiripentol

1 interaction

Monitor/Modify Tx

tazemetostat + stiripentol

monitor CBC: combo may decr. tazemetostat levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism possibly induced; additive effects)

• succimer
Tazverik (tazemetostat)

+

succimer

1 interaction

Monitor/Modify Tx

tazemetostat + succimer

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sulfasalazine
Tazverik (tazemetostat)

+

sulfasalazine

1 interaction

Monitor/Modify Tx

tazemetostat + sulfasalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tacrolimus
Tazverik (tazemetostat)

+

tacrolimus

1 interaction

Monitor/Modify Tx

tazemetostat + tacrolimus

monitor tacrolimus levels: combo may decr. tacrolimus levels, efficacy (hepatic metabolism induced)

• taletrectinib
Tazverik (tazemetostat)

+

taletrectinib

1 interaction

Monitor/Modify Tx

tazemetostat + taletrectinib

monitor ECG, electrolytes: combo may decr. taletrectinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

• telavancin
Tazverik (tazemetostat)

+

telavancin

1 interaction

Monitor/Modify Tx

tazemetostat + telavancin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• teplizumab
Tazverik (tazemetostat)

+

teplizumab

1 interaction

Monitor/Modify Tx

tazemetostat + teplizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• teriflunomide
Tazverik (tazemetostat)

+

teriflunomide

1 interaction

Monitor/Modify Tx

tazemetostat + teriflunomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tetrabenazine
Tazverik (tazemetostat)

+

tetrabenazine

1 interaction

Monitor/Modify Tx

tazemetostat + tetrabenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• thalidomide
Tazverik (tazemetostat)

+

thalidomide

1 interaction

Monitor/Modify Tx

tazemetostat + thalidomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tiagabine
Tazverik (tazemetostat)

+

tiagabine

1 interaction

Monitor/Modify Tx

tazemetostat + tiagabine

consider tiagabine dose adjustment if not on concurrent enzyme-inducing AEDs; titrate tiagabine dose to effect if already on enzyme-inducing AEDs: combo may decr. tiagabine levels, efficacy (hepatic metabolism induced; further induction possible if on concurrent enzyme-inducing AEDs)

• tocilizumab
Tazverik (tazemetostat)

+

tocilizumab

1 interaction

Monitor/Modify Tx

tazemetostat + tocilizumab

monitor CBC: combo may decr. tazemetostat levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes; additive effects)

• tofacitinib
Tazverik (tazemetostat)

+

tofacitinib

1 interaction

Monitor/Modify Tx

tazemetostat + tofacitinib

monitor CBC: combo may decr. tofacitinib levels, efficacy; may incr. risk of myelosuppression (hepatic metabolism induced; additive effects)

• triclabendazole
Tazverik (tazemetostat)

+

triclabendazole

1 interaction

Monitor/Modify Tx

tazemetostat + triclabendazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Tazverik (tazemetostat)

+

trifluridine

1 interaction

Monitor/Modify Tx

tazemetostat + trifluridine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trimethoprim
Tazverik (tazemetostat)

+

trimethoprim

1 interaction

Monitor/Modify Tx

tazemetostat + trimethoprim

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• triptorelin
Tazverik (tazemetostat)

+

triptorelin

1 interaction

Monitor/Modify Tx

tazemetostat + triptorelin

PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ubrogepant
Tazverik (tazemetostat)

+

ubrogepant

1 interaction

Monitor/Modify Tx

tazemetostat + ubrogepant

increase ubrogepant dose to 100 mg, may give second 100 mg dose after 2h if needed: combo may decr. ubrogepant levels, efficacy (hepatic metabolism induced)

• upadacitinib
Tazverik (tazemetostat)

+

upadacitinib

1 interaction

Monitor/Modify Tx

tazemetostat + upadacitinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• valproic acid
Tazverik (tazemetostat)

+

valproic acid

1 interaction

Monitor/Modify Tx

tazemetostat + valproic acid

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• vancomycin
Tazverik (tazemetostat)

+

vancomycin

1 interaction

Monitor/Modify Tx

tazemetostat + vancomycin

VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

• vemurafenib
Tazverik (tazemetostat)

+

vemurafenib

1 interaction

Monitor/Modify Tx

tazemetostat + vemurafenib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. tazemetostat levels, efficacy (additive effects; hepatic metabolism induced)

• warfarin
Tazverik (tazemetostat)

+

warfarin

1 interaction

Monitor/Modify Tx

tazemetostat + warfarin

monitor INR: combo may decr. warfarin levels, efficacy (hepatic metabolism induced)

• zidovudine
Tazverik (tazemetostat)

+

zidovudine

1 interaction

Monitor/Modify Tx

tazemetostat + zidovudine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ziftomenib
Tazverik (tazemetostat)

+

ziftomenib

1 interaction

Monitor/Modify Tx

tazemetostat + ziftomenib

monitor ECG, electrolytes: combo may decr. ziftomenib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

Caution Advised

• abemaciclib
Tazverik (tazemetostat)

+

abemaciclib

1 interaction

Caution Advised

tazemetostat + abemaciclib

caution advised: combo may decr. abemaciclib levels, efficacy (hepatic metabolism induced)

• acalabrutinib
Tazverik (tazemetostat)

+

acalabrutinib

1 interaction

Caution Advised

tazemetostat + acalabrutinib

caution advised: combo may decr. acalabrutinib levels, efficacy (hepatic metabolism induced)

• alfentanil
Tazverik (tazemetostat)

+

alfentanil

1 interaction

Caution Advised

tazemetostat + alfentanil

caution advised: combo may decr. alfentanil levels, efficacy (hepatic metabolism induced)

• alprazolam
Tazverik (tazemetostat)

+

alprazolam

1 interaction

Caution Advised

tazemetostat + alprazolam

caution advised: combo may decr. alprazolam levels, efficacy (hepatic metabolism induced)

• armodafinil
Tazverik (tazemetostat)

+

armodafinil

1 interaction

Caution Advised

tazemetostat + armodafinil

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• atorvastatin
Tazverik (tazemetostat)

+

atorvastatin

1 interaction

Caution Advised

tazemetostat + atorvastatin

caution advised: combo may decr. atorvastatin levels, efficacy (hepatic metabolism induced)

• avapritinib
Tazverik (tazemetostat)

+

avapritinib

1 interaction

Caution Advised

tazemetostat + avapritinib

caution advised: combo may decr. avapritinib levels, efficacy (hepatic metabolism induced)

• axitinib
Tazverik (tazemetostat)

+

axitinib

1 interaction

Caution Advised

tazemetostat + axitinib

caution advised: combo may decr. axitinib levels, efficacy (hepatic metabolism induced)

• belzutifan
Tazverik (tazemetostat)

+

belzutifan

1 interaction

Caution Advised

tazemetostat + belzutifan

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• bexarotene
Tazverik (tazemetostat)

+

bexarotene

1 interaction

Caution Advised

tazemetostat + bexarotene

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• bictegravir
Tazverik (tazemetostat)

+

bictegravir

1 interaction

Caution Advised

tazemetostat + bictegravir

caution advised if also combined w/ UGT1A1 inducer: combo may decr. bictegravir levels, efficacy (hepatic metabolism induced)

• bosutinib
Tazverik (tazemetostat)

+

bosutinib

1 interaction

Caution Advised

tazemetostat + bosutinib

caution advised: combo may decr. bosutinib levels, efficacy (hepatic metabolism induced)

• brigatinib
Tazverik (tazemetostat)

+

brigatinib

1 interaction

Caution Advised

tazemetostat + brigatinib

caution advised: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• budesonide
Tazverik (tazemetostat)

+

budesonide

1 interaction

Caution Advised

tazemetostat + budesonide

caution advised: combo may decr. budesonide levels, efficacy (hepatic metabolism induced)

• buspirone
Tazverik (tazemetostat)

+

buspirone

1 interaction

Caution Advised

tazemetostat + buspirone

caution advised: combo may decr. buspirone levels, efficacy (hepatic metabolism induced)

• capivasertib
Tazverik (tazemetostat)

+

capivasertib

1 interaction

Caution Advised

tazemetostat + capivasertib

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• capmatinib
Tazverik (tazemetostat)

+

capmatinib

1 interaction

Caution Advised

tazemetostat + capmatinib

caution advised: combo may decr. capmatinib levels, efficacy (hepatic metabolism induced)

• clobazam
Tazverik (tazemetostat)

+

clobazam

1 interaction

Caution Advised

tazemetostat + clobazam

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• cobimetinib
Tazverik (tazemetostat)

+

cobimetinib

1 interaction

Caution Advised

tazemetostat + cobimetinib

caution advised: combo may decr. cobimetinib levels, efficacy (hepatic metabolism induced)

• danshen
Tazverik (tazemetostat)

+

danshen

1 interaction

Caution Advised

tazemetostat + danshen

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• daridorexant
Tazverik (tazemetostat)

+

daridorexant

1 interaction

Caution Advised

tazemetostat + daridorexant

caution advised: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• darolutamide
Tazverik (tazemetostat)

+

darolutamide

1 interaction

Caution Advised

tazemetostat + darolutamide

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• dasatinib
Tazverik (tazemetostat)

+

dasatinib

1 interaction

Caution Advised

tazemetostat + dasatinib

caution advised: combo may decr. dasatinib levels, efficacy (hepatic metabolism induced)

• defactinib
Tazverik (tazemetostat)

+

defactinib

1 interaction

Caution Advised

tazemetostat + defactinib

caution advised: combo may decr. defactinib levels, efficacy (hepatic metabolism induced)

• deflazacort
Tazverik (tazemetostat)

+

deflazacort

1 interaction

Caution Advised

tazemetostat + deflazacort

caution advised: combo may decr. deflazacort active metabolite levels, efficacy (hepatic metabolism induced)

• dexamethasone
Tazverik (tazemetostat)

+

dexamethasone

1 interaction

Caution Advised

tazemetostat + dexamethasone

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• dicloxacillin
Tazverik (tazemetostat)

+

dicloxacillin

1 interaction

Caution Advised

tazemetostat + dicloxacillin

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• doravirine
Tazverik (tazemetostat)

+

doravirine

1 interaction

Caution Advised

tazemetostat + doravirine

caution advised: combo may decr. doravirine levels, efficacy (hepatic metabolism induced)

• drospirenone (hormone replacement)
Tazverik (tazemetostat)

+

drospirenone (hormone replacement)

1 interaction

Caution Advised

tazemetostat + drospirenone (hormone replacement)

caution advised: combo may decr. drospirenone levels, efficacy (hepatic metabolism induced)

• echinacea
Tazverik (tazemetostat)

+

echinacea

1 interaction

Caution Advised

tazemetostat + echinacea

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• elacestrant
Tazverik (tazemetostat)

+

elacestrant

1 interaction

Caution Advised

tazemetostat + elacestrant

caution advised: combo may decr. elacestrant levels, efficacy (hepatic metabolism induced)

• elafibranor
Tazverik (tazemetostat)

+

elafibranor

1 interaction

Caution Advised

tazemetostat + elafibranor

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• elbasvir
Tazverik (tazemetostat)

+

elbasvir

1 interaction

Caution Advised

tazemetostat + elbasvir

caution advised: combo may decr. elbasvir levels, efficacy (hepatic metabolism induced)

• elexacaftor/tezacaftor/ivacaftor
Tazverik (tazemetostat)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Caution Advised

tazemetostat + elexacaftor/ tezacaftor/ ivacaftor

caution advised: combo may decr. elexacaftor/tezacaftor/ivacaftor levels, efficacy (hepatic metabolism induced)

• eliglustat
Tazverik (tazemetostat)

+

eliglustat

1 interaction

Caution Advised

tazemetostat + eliglustat

caution advised: combo may decr. eliglustat levels, efficacy (hepatic metabolism induced)

• elvitegravir
Tazverik (tazemetostat)

+

elvitegravir

1 interaction

Caution Advised

tazemetostat + elvitegravir

caution advised: combo may decr. elvitegravir levels, efficacy (hepatic metabolism induced)

• enasidenib
Tazverik (tazemetostat)

+

enasidenib

1 interaction

Caution Advised

tazemetostat + enasidenib

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• entrectinib
Tazverik (tazemetostat)

+

entrectinib

1 interaction

Caution Advised

tazemetostat + entrectinib

caution advised: combo may decr. entrectinib levels, efficacy (hepatic metabolism induced)

• erdafitinib
Tazverik (tazemetostat)

+

erdafitinib

1 interaction

Caution Advised

tazemetostat + erdafitinib

caution advised: combo may decr. erdafitinib levels, efficacy (hepatic metabolism induced)

• erlotinib
Tazverik (tazemetostat)

+

erlotinib

1 interaction

Caution Advised

tazemetostat + erlotinib

caution advised: combo may decr. erlotinib levels, efficacy (hepatic metabolism induced)

• eslicarbazepine acetate
Tazverik (tazemetostat)

+

eslicarbazepine acetate

1 interaction

Caution Advised

tazemetostat + eslicarbazepine acetate

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• felbamate
Tazverik (tazemetostat)

+

felbamate

1 interaction

Caution Advised

tazemetostat + felbamate

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• felodipine
Tazverik (tazemetostat)

+

felodipine

1 interaction

Caution Advised

tazemetostat + felodipine

caution advised: combo may decr. felodipine levels, efficacy (hepatic metabolism induced)

• finerenone
Tazverik (tazemetostat)

+

finerenone

1 interaction

Caution Advised

tazemetostat + finerenone

caution advised: combo may decr. finerenone levels, efficacy (hepatic metabolism induced)

• fosaprepitant
Tazverik (tazemetostat)

+

fosaprepitant

1 interaction

Caution Advised

tazemetostat + fosaprepitant

caution advised: combo may decr. aprepitant levels, efficacy (hepatic metabolism induced)

• fruquintinib
Tazverik (tazemetostat)

+

fruquintinib

1 interaction

Caution Advised

tazemetostat + fruquintinib

caution advised: combo may decr. fruquintinib levels, efficacy (hepatic metabolism induced)

• garlic
Tazverik (tazemetostat)

+

garlic

1 interaction

Caution Advised

tazemetostat + garlic

caution advised w/ supplemental garlic; dietary intake OK: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• gepirone
Tazverik (tazemetostat)

+

gepirone

1 interaction

Caution Advised

tazemetostat + gepirone

caution advised: combo may decr. gepirone levels, efficacy (hepatic metabolism induced)

• ginkgo
Tazverik (tazemetostat)

+

ginkgo

1 interaction

Caution Advised

tazemetostat + ginkgo

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• ginseng, Asian
Tazverik (tazemetostat)

+

ginseng, Asian

1 interaction

Caution Advised

tazemetostat + ginseng, Asian

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• glecaprevir
Tazverik (tazemetostat)

+

glecaprevir

1 interaction

Caution Advised

tazemetostat + glecaprevir

caution advised: combo may decr. glecaprevir levels, efficacy (hepatic metabolism induced)

• glycerol phenylbutyrate
Tazverik (tazemetostat)

+

glycerol phenylbutyrate

1 interaction

Caution Advised

tazemetostat + glycerol phenylbutyrate

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• grazoprevir
Tazverik (tazemetostat)

+

grazoprevir

1 interaction

Caution Advised

tazemetostat + grazoprevir

caution advised: combo may decr. grazoprevir levels, efficacy (hepatic metabolism induced)

• griseofulvin
Tazverik (tazemetostat)

+

griseofulvin

1 interaction

Caution Advised

tazemetostat + griseofulvin

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• guanfacine
Tazverik (tazemetostat)

+

guanfacine

1 interaction

Caution Advised

tazemetostat + guanfacine

caution advised: combo may decr. guanfacine levels, efficacy (hepatic metabolism induced)

• hydrocortisone
Tazverik (tazemetostat)

+

hydrocortisone

1 interaction

Caution Advised

tazemetostat + hydrocortisone

caution advised: combo may decr. hydrocortisone levels, efficacy (hepatic metabolism induced)

• ibrutinib
Tazverik (tazemetostat)

+

ibrutinib

1 interaction

Caution Advised

tazemetostat + ibrutinib

caution advised: combo may decr. ibrutinib levels, efficacy (hepatic metabolism induced)

• irinotecan
Tazverik (tazemetostat)

+

irinotecan

1 interaction

Caution Advised

tazemetostat + irinotecan

caution advised: combo may decr. irinotecan and active metabolite levels, efficacy (hepatic metabolism induced)

• istradefylline
Tazverik (tazemetostat)

+

istradefylline

1 interaction

Caution Advised

tazemetostat + istradefylline

caution advised: combo may decr. istradefylline levels, efficacy (hepatic metabolism induced)

• ivacaftor
Tazverik (tazemetostat)

+

ivacaftor

1 interaction

Caution Advised

tazemetostat + ivacaftor

caution advised: combo may decr. ivacaftor levels, efficacy (hepatic metabolism induced)

• lapatinib
Tazverik (tazemetostat)

+

lapatinib

1 interaction

Caution Advised

tazemetostat + lapatinib

caution advised: combo may decr. lapatinib levels, efficacy (hepatic metabolism induced)

• larotrectinib
Tazverik (tazemetostat)

+

larotrectinib

1 interaction

Caution Advised

tazemetostat + larotrectinib

caution advised: combo may decr. larotrectinib levels, efficacy (hepatic metabolism induced)

• lazertinib
Tazverik (tazemetostat)

+

lazertinib

1 interaction

Caution Advised

tazemetostat + lazertinib

caution advised: combo may decr. lazertinib levels, efficacy (hepatic metabolism induced)

• leniolisib
Tazverik (tazemetostat)

+

leniolisib

1 interaction

Caution Advised

tazemetostat + leniolisib

caution advised: combo may decr. leniolisib levels, efficacy (hepatic metabolism induced)

• levonorgestrel intrauterine device (contraceptive)
Tazverik (tazemetostat)

+

levonorgestrel intrauterine device (contraceptive)

1 interaction

Caution Advised

tazemetostat + levonorgestrel intrauterine device (contraceptive)

caution advised: combo may decr. levonorgestrel levels, contraceptive efficacy (hepatic metabolism possibly induced)

• lurasidone
Tazverik (tazemetostat)

+

lurasidone

1 interaction

Caution Advised

tazemetostat + lurasidone

caution advised: combo may decr. lurasidone levels, efficacy (hepatic metabolism induced)

• macitentan
Tazverik (tazemetostat)

+

macitentan

1 interaction

Caution Advised

tazemetostat + macitentan

caution advised: combo may decr. macitentan levels, efficacy (hepatic metabolism induced)

• maraviroc
Tazverik (tazemetostat)

+

maraviroc

1 interaction

Caution Advised

tazemetostat + maraviroc

caution advised: combo may decr. maraviroc levels, efficacy (hepatic metabolism induced)

• meropenem
Tazverik (tazemetostat)

+

meropenem

1 interaction

Caution Advised

tazemetostat + meropenem

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism possibly induced)

• midazolam
Tazverik (tazemetostat)

+

midazolam

1 interaction

Caution Advised

tazemetostat + midazolam

caution advised w/ oral midazolam; other midazolam routes OK: combo may decr. midazolam levels, efficacy (hepatic metabolism induced)

• midostaurin
Tazverik (tazemetostat)

+

midostaurin

1 interaction

Caution Advised

tazemetostat + midostaurin

caution advised: combo may decr. midostaurin levels, efficacy (hepatic metabolism induced)

• naldemedine
Tazverik (tazemetostat)

+

naldemedine

1 interaction

Caution Advised

tazemetostat + naldemedine

caution advised: combo may decr. naldemedine levels, efficacy (hepatic metabolism induced)

• naloxegol
Tazverik (tazemetostat)

+

naloxegol

1 interaction

Caution Advised

tazemetostat + naloxegol

caution advised: combo may decr. naloxegol levels, efficacy (hepatic metabolism induced)

• neratinib
Tazverik (tazemetostat)

+

neratinib

1 interaction

Caution Advised

tazemetostat + neratinib

caution advised: combo may decr. neratinib levels, efficacy (hepatic metabolism induced)

• nevirapine
Tazverik (tazemetostat)

+

nevirapine

1 interaction

Caution Advised

tazemetostat + nevirapine

caution advised: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• nifedipine
Tazverik (tazemetostat)

+

nifedipine

1 interaction

Caution Advised

tazemetostat + nifedipine

caution advised: combo may decr. nifedipine levels, efficacy (hepatic metabolism induced)

• nirmatrelvir
Tazverik (tazemetostat)

+

nirmatrelvir

1 interaction

Caution Advised

tazemetostat + nirmatrelvir

caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

• odevixibat
Tazverik (tazemetostat)

+

odevixibat

1 interaction

Caution Advised

tazemetostat + odevixibat

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• olaparib
Tazverik (tazemetostat)

+

olaparib

1 interaction

Caution Advised

tazemetostat + olaparib

caution advised: combo may decr. olaparib levels, efficacy (hepatic metabolism induced)

• olutasidenib
Tazverik (tazemetostat)

+

olutasidenib

1 interaction

Caution Advised

tazemetostat + olutasidenib

caution advised: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• omaveloxolone
Tazverik (tazemetostat)

+

omaveloxolone

1 interaction

Caution Advised

tazemetostat + omaveloxolone

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• oxcarbazepine
Tazverik (tazemetostat)

+

oxcarbazepine

1 interaction

Caution Advised

tazemetostat + oxcarbazepine

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• palbociclib
Tazverik (tazemetostat)

+

palbociclib

1 interaction

Caution Advised

tazemetostat + palbociclib

caution advised: combo may decr. palbociclib levels, efficacy (hepatic metabolism induced)

• pemigatinib
Tazverik (tazemetostat)

+

pemigatinib

1 interaction

Caution Advised

tazemetostat + pemigatinib

caution advised: combo may decr. pemigatinib levels, efficacy (hepatic metabolism induced)

• perampanel
Tazverik (tazemetostat)

+

perampanel

1 interaction

Caution Advised

tazemetostat + perampanel

caution advised: combo may decr. perampanel levels, efficacy; may decr. tazemetostat levels, efficacy if on perampanel 12 mg/day (hepatic metabolism induced)

• pimavanserin
Tazverik (tazemetostat)

+

pimavanserin

1 interaction

Caution Advised

tazemetostat + pimavanserin

caution advised: combo may decr. pimavanserin levels, efficacy (hepatic metabolism induced)

• pioglitazone
Tazverik (tazemetostat)

+

pioglitazone

1 interaction

Caution Advised

tazemetostat + pioglitazone

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• pirtobrutinib
Tazverik (tazemetostat)

+

pirtobrutinib

1 interaction

Caution Advised

tazemetostat + pirtobrutinib

caution advised: combo may decr. pirtobrutinib levels, efficacy (hepatic metabolism induced)

• ponatinib
Tazverik (tazemetostat)

+

ponatinib

1 interaction

Caution Advised

tazemetostat + ponatinib

caution advised: combo may decr. ponatinib levels, efficacy (hepatic metabolism induced)

• praziquantel
Tazverik (tazemetostat)

+

praziquantel

1 interaction

Caution Advised

tazemetostat + praziquantel

caution advised: combo may decr. praziquantel levels, efficacy (hepatic metabolism induced)

• prednisone
Tazverik (tazemetostat)

+

prednisone

1 interaction

Caution Advised

tazemetostat + prednisone

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• pretomanid
Tazverik (tazemetostat)

+

pretomanid

1 interaction

Caution Advised

tazemetostat + pretomanid

caution advised: combo may decr. pretomanid levels, efficacy (hepatic metabolism induced)

• quetiapine
Tazverik (tazemetostat)

+

quetiapine

1 interaction

Caution Advised

tazemetostat + quetiapine

caution advised: combo may decr. quetiapine levels, efficacy (hepatic metabolism induced)

• rilpivirine
Tazverik (tazemetostat)

+

rilpivirine

1 interaction

Caution Advised

tazemetostat + rilpivirine

caution advised: combo may decr. rilpivirine levels, efficacy (hepatic metabolism induced)

• ripretinib
Tazverik (tazemetostat)

+

ripretinib

1 interaction

Caution Advised

tazemetostat + ripretinib

caution advised: combo may decr. ripretinib and active metabolite levels, efficacy (hepatic metabolism induced)

• roflumilast
Tazverik (tazemetostat)

+

roflumilast

1 interaction

Caution Advised

tazemetostat + roflumilast

caution advised: combo may decr. roflumilast levels, efficacy (hepatic metabolism induced)

• rolapitant
Tazverik (tazemetostat)

+

rolapitant

1 interaction

Caution Advised

tazemetostat + rolapitant

caution advised: combo may decr. rolapitant levels, efficacy (hepatic metabolism induced)

• rufinamide
Tazverik (tazemetostat)

+

rufinamide

1 interaction

Caution Advised

tazemetostat + rufinamide

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• samidorphan
Tazverik (tazemetostat)

+

samidorphan

1 interaction

Caution Advised

tazemetostat + samidorphan

caution advised: combo may decr. samidorphan levels, efficacy (hepatic metabolism induced)

• sebetralstat
Tazverik (tazemetostat)

+

sebetralstat

1 interaction

Caution Advised

tazemetostat + sebetralstat

caution advised: combo may decr. sebetralstat levels, efficacy (hepatic metabolism induced)

• selumetinib
Tazverik (tazemetostat)

+

selumetinib

1 interaction

Caution Advised

tazemetostat + selumetinib

caution advised: combo may decr. selumetinib levels, efficacy (hepatic metabolism induced)

• simvastatin
Tazverik (tazemetostat)

+

simvastatin

1 interaction

Caution Advised

tazemetostat + simvastatin

caution advised: combo may decr. simvastatin levels, efficacy (hepatic metabolism induced)

• sirolimus albumin-bound
Tazverik (tazemetostat)

+

sirolimus albumin-bound

1 interaction

Caution Advised

tazemetostat + sirolimus albumin-bound

caution advised: combo may decr. sirolimus albumin-bound levels, efficacy (hepatic metabolism induced)

• sonidegib
Tazverik (tazemetostat)

+

sonidegib

1 interaction

Caution Advised

tazemetostat + sonidegib

caution advised: combo may decr. sonidegib levels, efficacy (hepatic metabolism induced)

• sunvozertinib
Tazverik (tazemetostat)

+

sunvozertinib

1 interaction

Caution Advised

tazemetostat + sunvozertinib

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• suzetrigine
Tazverik (tazemetostat)

+

suzetrigine

1 interaction

Caution Advised

tazemetostat + suzetrigine

caution advised: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• tadalafil
Tazverik (tazemetostat)

+

tadalafil

1 interaction

Caution Advised

tazemetostat + tadalafil

caution advised: combo may decr. tadalafil levels, efficacy (hepatic metabolism induced)

• tamoxifen
Tazverik (tazemetostat)

+

tamoxifen

1 interaction

Caution Advised

tazemetostat + tamoxifen

caution advised: combo may decr. tamoxifen and active metabolite levels, efficacy (hepatic metabolism induced)

• tasimelteon
Tazverik (tazemetostat)

+

tasimelteon

1 interaction

Caution Advised

tazemetostat + tasimelteon

caution advised: combo may decr. tasimelteon levels, efficacy (hepatic metabolism induced)

• tecovirimat
Tazverik (tazemetostat)

+

tecovirimat

1 interaction

Caution Advised

tazemetostat + tecovirimat

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• telotristat ethyl
Tazverik (tazemetostat)

+

telotristat ethyl

1 interaction

Caution Advised

tazemetostat + telotristat ethyl

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• temsirolimus
Tazverik (tazemetostat)

+

temsirolimus

1 interaction

Caution Advised

tazemetostat + temsirolimus

caution advised: combo may decr. temsirolimus and active metabolite sirolimus levels, efficacy (hepatic metabolism induced)

• tezacaftor/ivacaftor
Tazverik (tazemetostat)

+

tezacaftor/ ivacaftor

1 interaction

Caution Advised

tazemetostat + tezacaftor/ ivacaftor

caution advised: combo may decr. tezacaftor/ivacaftor levels, efficacy (hepatic metabolism induced)

• ticagrelor
Tazverik (tazemetostat)

+

ticagrelor

1 interaction

Caution Advised

tazemetostat + ticagrelor

caution advised: combo may decr. ticagrelor levels, efficacy (hepatic metabolism induced)

• tolvaptan
Tazverik (tazemetostat)

+

tolvaptan

1 interaction

Caution Advised

tazemetostat + tolvaptan

caution advised: combo may decr. tolvaptan levels, efficacy (hepatic metabolism induced)

• topiramate
Tazverik (tazemetostat)

+

topiramate

1 interaction

Caution Advised

tazemetostat + topiramate

caution advised, especially w/ topiramate doses >200 mg/day: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• tovorafenib
Tazverik (tazemetostat)

+

tovorafenib

1 interaction

Caution Advised

tazemetostat + tovorafenib

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• vaborbactam
Tazverik (tazemetostat)

+

vaborbactam

1 interaction

Caution Advised

tazemetostat + vaborbactam

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism possibly induced)

• vamorolone
Tazverik (tazemetostat)

+

vamorolone

1 interaction

Caution Advised

tazemetostat + vamorolone

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism possibly induced)

• vanzacaftor/tezacaftor/deutivacaftor
Tazverik (tazemetostat)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Caution Advised

tazemetostat + vanzacaftor/ tezacaftor/ deutivacaftor

caution advised: combo may decr. vanzacaftor/tezacaftor/deutivacaftor levels, efficacy (hepatic metabolism induced)

• velpatasvir
Tazverik (tazemetostat)

+

velpatasvir

1 interaction

Caution Advised

tazemetostat + velpatasvir

caution advised: combo may decr. velpatasvir levels, efficacy (hepatic metabolism induced)

• venetoclax
Tazverik (tazemetostat)

+

venetoclax

1 interaction

Caution Advised

tazemetostat + venetoclax

caution advised: combo may decr. venetoclax levels, efficacy (hepatic metabolism induced)

• vinblastine
Tazverik (tazemetostat)

+

vinblastine

1 interaction

Caution Advised

tazemetostat + vinblastine

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism induced)

• voclosporin
Tazverik (tazemetostat)

+

voclosporin

1 interaction

Caution Advised

tazemetostat + voclosporin

caution advised: combo may decr. voclosporin levels, efficacy (hepatic metabolism induced)

• vonoprazan
Tazverik (tazemetostat)

+

vonoprazan

1 interaction

Caution Advised

tazemetostat + vonoprazan

caution advised: combo may decr. vonoprazan levels, efficacy (hepatic metabolism induced)

• vorasidenib
Tazverik (tazemetostat)

+

vorasidenib

1 interaction

Caution Advised

tazemetostat + vorasidenib

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metabolism possibly induced)

• voxilaprevir
Tazverik (tazemetostat)

+

voxilaprevir

1 interaction

Caution Advised

tazemetostat + voxilaprevir

caution advised: combo may decr. voxilaprevir levels, efficacy (hepatic metabolism induced)

• zanubrutinib
Tazverik (tazemetostat)

+

zanubrutinib

1 interaction

Caution Advised

tazemetostat + zanubrutinib

caution advised: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)